Brief: Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism

Corcept Therapeutics Incorporated

31/12/2025 13:06

Dec 31 (Reuters) - Corcept Therapeutics Inc CORT.O:

CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM

CORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDA

CORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVAL

Source text: ID:nBw1PW1h4a

Further company coverage: CORT.O

 ((Reuters.Briefs@thomsonreuters.com;))